Evaluation of step-down therapy from an inhaled steroid to montelukast in childhood asthma

After treatment switch from low-dose ICS to montelukast, asthma control was maintained in the majority of patients during the 12-week observation period. Sputum eosinophilia or BHR before the treatment switch was exacerbation risk factor.